SPINOZA. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma

Trial Profile

SPINOZA. Study With Preparatory INduction Of Zevalin in Aggressive Lymphoma. A Randomized Phase 3 Study of BEAM Versus 90Yttrium Ibritumomab Tiuxetan (Zevalin) / BEAM in Patients Requiring Autologous Hematopoietic Stem Cell Transplantation (ASCT) for Relapsed Diffuse Large B-cell Lymphoma

Discontinued
Phase of Trial: Phase III

Latest Information Update: 10 Oct 2016

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Autologous stem cell therapy; Carmustine; Cytarabine; Etoposide; Melphalan
  • Indications Diffuse large B cell lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Acronyms Spinoza
  • Most Recent Events

    • 06 Oct 2016 Status changed from active, no longer recruiting to discontinued due to wthdrawal of sponsor support.
    • 05 Aug 2016 Status changed from recruiting to active, no longer recruiting.
    • 26 Feb 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top